دورية أكاديمية
182TiP Effectiveness of niraparib plus aromatase inhibitors (AI) for germinal BRCA1/2-mutated (gBRCAm) or homologous recombination deficient (HRD), hormone receptor (HR)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer (ABC). The LUZERN Strategy
| العنوان: | 182TiP Effectiveness of niraparib plus aromatase inhibitors (AI) for germinal BRCA1/2-mutated (gBRCAm) or homologous recombination deficient (HRD), hormone receptor (HR)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer (ABC). The LUZERN Strategy |
|---|---|
| المؤلفون: | Blanch, S., Pérez-García, J.M., Balmaña, J., Prat, A., Alés-Martínez, J.E., de la Haba, J., Alba, E., Palacios-Ozores, P., Ramos, M., Lema, L., García Sáenz, J.Á., Sampayo-Cordero, M., Malfettone, A., Cortés, J., Llombart Cussac, A. |
| المصدر: | Annals of Oncology ; volume 31, page S82 ; ISSN 0923-7534 |
| بيانات النشر: | Elsevier BV |
| سنة النشر: | 2020 |
| المجموعة: | ScienceDirect (Elsevier - Open Access Articles via Crossref) |
| مصطلحات موضوعية: | Oncology, Hematology |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1016/j.annonc.2020.03.282 |
| الإتاحة: | https://doi.org/10.1016/j.annonc.2020.03.282Test https://api.elsevier.com/content/article/PII:S0923753420363614?httpAccept=text/xmlTest https://api.elsevier.com/content/article/PII:S0923753420363614?httpAccept=text/plainTest |
| حقوق: | https://www.elsevier.com/tdm/userlicense/1.0Test/ ; http://www.elsevier.com/open-access/userlicense/1.0Test/ |
| رقم الانضمام: | edsbas.DF402069 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.annonc.2020.03.282 |
|---|